Verastem (VSTM) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress
October 29, 2019 4:17 PM EDTCompany Reports $9 Million in Total Revenue, including $4.0 Million in Net Product Revenue from COPIKTRA®; Reaffirms FY2019 Revenue Guidance
Cash, Cash Equivalents and Short-Term Investments of $160.2 Million as of September 30, 2019
Company to Streamline Organization and Reduce Operating Expenses by $25 Million in 2020
Company to Host Conference Call Today at 4:30 PM ET
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (Nasdaq: VSTM), operating as Verastem Oncology (or the Company), focused on developing and commercializing medicines seeking to improve the survival and quality of... More
